应世生物冲刺港交所：核心产品有望成为中国首个获批的选择性FAK抑制剂

Core Viewpoint - InxMed Limited, a late-stage biotech company, focuses on improving cancer treatment paradigms by targeting key signaling pathways, particularly FAK and integrin pathways, to address unmet medical needs in oncology [2][4]. Product Pipeline - The company has a robust pipeline including its core product ifebemtinib, a highly selective FAK inhibitor, which is nearing commercialization and is expected to be the first approved selective FAK inhibitor in China and the second globally [4][5]. - Ifebemtinib has received regulatory recognition, including FDA Fast Track designation and NMPA Breakthrough Therapy designation for various cancer treatments, indicating its potential as a cornerstone therapy in multiple cancer treatment regimens [5][6]. - Other pipeline assets include IN10028 (a second-generation selective FAK inhibitor), OMTX705, IN30758, and IN30778, which are designed to complement existing therapies and maintain a competitive edge in the oncology market [6][7]. Market Potential - The global market for selective FAK inhibitors is projected to grow at a compound annual growth rate (CAGR) of 71.1%, reaching $5.562 billion by 2035, while the Chinese market is expected to grow at a CAGR of 54.6%, reaching $1.571 billion by 2035 [5][6]. Commercialization Strategy - Since 2022, the company has established strong partnerships with top clinical institutions and key opinion leaders in China, laying a solid foundation for the successful commercialization of its products [7][8]. - The company has raised over 929 million RMB from notable investors, enhancing its financial position ahead of its IPO [8][9]. Financial Overview - Following the last round of financing before the IPO, the company's valuation stands at $306 million, with net proceeds from the IPO primarily allocated to the development and regulatory approval of ifebemtinib and other pipeline assets [9][10].